0.082
0.00 (0.00%)
| Previous Close | 0.082 |
| Open | 0.082 |
| Volume | 16,504 |
| Avg. Volume (3M) | 19,971 |
| Market Cap | 2,677,021 |
| Price / Sales | 0.330 |
| Price / Book | 3.84 |
| 52 Weeks Range | |
| Earnings Date | 28 Aug 2024 - 2 Sep 2024 |
| Profit Margin | -106.79% |
| Operating Margin (TTM) | -56.43% |
| Diluted EPS (TTM) | -0.180 |
| Quarterly Revenue Growth (YOY) | 137.00% |
| Current Ratio (MRQ) | 0.090 |
| Operating Cash Flow (TTM) | -2.45 M |
| Levered Free Cash Flow (TTM) | -1.33 M |
| Return on Assets (TTM) | -109.93% |
| Return on Equity (TTM) | -2,804.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (AU) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | IMAGIONBIO FPO [IBX] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.50 |
|
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.43% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |